The Petit Institute is the home of many research centers. The Petit Institute's role is to provide infrastructure to support research centers so that each center does not have to try to maintain their own staff and resources. Support comes in the form of access to core facility usage as well as other services such as accounting, marketing and website support, event planning, multi-investigator proposal development, industry relations and tech transfer to facilitate center operation.
The Atlantic Pediatric Device Consortium (APDC) is partially funded by the FDA Office of Orphan Projects Development and provides a national platform to translate ideas through the product development pathway all the way to commercialization. Our mission is to enhance the lives of children through the development of novel pediatric medical devices which are both safe and effective. The Consortium fosters an environment of creativity, where innovative ideas will be reviewed, tested and developed.
CMaT will enable robust, scalable, low-cost biomanufacturing of high-quality therapeutic cells to bring affordable, curative therapies against incurable chronic diseases to everyone.
This will transform healthcare, improve the economy, add new jobs, and enhance national security.
The goal of the Bio Imaging Mass Spectrometry Initiative (BIMS) is to further the development of techniques, instrumentation and the fundamental understanding of mass spectrometry used to produce 2D and 3D images of biological samples. These meetings will also provide an outlet to discus success as well as trouble shoot difficulties encountered while undertaking projects related to this research.
How life began is arguably the most intriguing question of our time. Determining the chemistry required for the de novo appearance of life is also an important scientific problem, as its solution will have a major impact on chemistry, other scientific fields and the general public. The long-term research objective of our CCI is to demonstrate that small molecules within a model inventory of prebiotic chemistry can self-assemble into polymers that resemble RNA and proteins. The members of this Center hold the common belief that achieving a “one pot” self-assembly of life-like polymers is a realistic goal.
The Center for Drug Design Development & Delivery, or CD4, is an incomparable center that seeks to provide new and refreshing ideas and interpretations to traditional pharmaceutical research. CD4 is making grand strides in accomplishing these efforts by operating through its three main projects: the Pharmaceutical Pipeline Project, the Vaccine Technology Project, and the Pharmaceutical Education Project.
At the Center for Immunoengineering at Georgia Tech engineers, chemists, physicists, computational scientists, and immunologists come together to collaboratively understand how the immune system works and find breakthrough solutions to improve the lives of patients suffering from cancer, infectious diseases (e.g. HIV, tuberculosis, hepatitis, polio etc.), autoimmune and inflammatory disorders (e.g. diabetes, lupus, multiple sclerosis, arthritis, fibrosis, asthma etc.) as well as those undergoing regenerative therapies (e.g. organ transplantation, spinal cord injury, bone and cartilage repair, etc.).
The Center for Innovative Cardiovascular Technologies (CICT) brings together the translational cardiac community in the greater Atlanta area. It will also have a tremendous impact on economic development in the State of Georgia. CICT is a key component of Georgia Tech’s overall strategy in Translational Biomedical Research to help make Atlanta a major center for innovations in health care.
The Center for Integrative Genomics (CIG) at Georgia Tech is a virtual affiliation of researchers interested in the application of genome-wide research strategies to diverse biological themes. The goals of the center are to: Conduct quantitative genetic analysis of Genomes, Transcriptomes, Proteomes, Metabolomes and Phenomes and foster partnerships within the School of Biology, across Georgia Tech, and with collaborators in the Atlanta region.
Accordingly, the Center will utilize the combined expertise of Georgia Tech and Emory University researchers who employ a variety of in vivo, in vitro and in silico approaches and represent different fields of study, including: genetics; molecular, cellular and structural biology; chemistry, biochemistry and synthetic biology; chemical, biomolecular and biomedical engineering; bioinformatics and computational biology. NanoMAD's mission is to develop new technologies for detecting, monitoring and controlling self-assembled macromolecular complexes at various levels, including their pathogenic consequences, biological roles and evolutionary origin.
The mission of the Center for Pediatric Innovation (CPI) is to develop new medical devices, therapeutics, and regenerative medicine strategies to address grand challenges and unmet clinical needs in pediatric healthcare. Industry has made significant advances in technologies that impact healthcare delivery, but for the most part these advances have targeted adult populations.
The Center for Pharmaceutical Development (CPD), established in February 2010, provides a forum for academic and industrial scientists to develop novel approaches for the improvement of pharmaceutical API manufacturing, for product formulation, and for analytical methods. The distinctive strengths of each of the University partners will provide industrial participants with unique opportunities to advance topics on the manufacturing, formulation and analysis of pharmaceuticals. The Center facilitates technologies such as the creation of more selective and robust biological and chemical catalysts that allow more streamlined processes, the development of improved methods for stabilizing drugs and vaccines to protect the nation’s drug supply, and the design of new techniques for the nondestructive evaluation of pharmaceutical products.
To reach this goal, the Center's research program has three components of increasing complexity, plus an enabling technologies thrust. EBICS' educational programs aim at producing the next generation of research and education leaders who are truly knowledgeable in both biology and engineering, and who will potentially shape how research and education are done in this new field. The Center will also engage faculty from minority-serving institutions on research projects, and work closely with existing outreach and recruitment programs at all partner institutions to ensure the broadest range of participation in all of its programs.
The Georgia Center for Medical Robotics (GCMR) brings together people with expertise in several areas of medicine as well as technology development from the nano-scale to macro-scale. GCMR is highly interdisciplinary, comprised of people from the Georgia Institute of Technology, Emory University, Children’s Healthcare of Atlanta (CHOA), and Morehouse School of Medicine. One of its unique features is that it addresses the needs of both adult and pediatric populations.
The mission of the Integrated Cancer Research Center (ICRC) is to facilitate integration of the diversity of technological, computational, scientific and medical expertise at Georgia Tech and partner institutions in a coordinated effort to develop improved cancer diagnostics and therapeutics.
Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M) is the first such research center in the United States. The current state-of-the-art in cell therapies involves small scale, hospital-centric processing of cells, operated with minimal characterization, and little involvement of process engineering and QA/QC concepts leading to wide variability and uncertainty in clinical trials. In addition to developing new tools and technologies, standards development will be a long term goal of Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M).
The Nanomedicine Center for Nucleoprotein Machines focuses on understanding and re-directing natural processes for repair of damaged DNA. Human cells have many different repair pathways, each of which involves a different type of nucleoprotein machine. The Center’s five-year goal is to re-engineer the homologous recombination repair machine to provide a clinically applicable gene correction technology. The Center’s vision is to design, produce, deliver, and validate a gene correction device based on engineered zinc finger nucleases. The device will home to the defective gene in the patient’s hematopoietic stem cells and make a precise cut to activate the HR machine, which will replace the mutation with the correct beta-globin sequence. The approach can potentially be extended for treatment of other single-gene disorders.
The Neural Engineering Center develops cutting-edge science and technology for measuring, understanding, modifying, and stimulating neural activity. There is a critical need for novel collaborative integration between researchers developing interfacing technologies and those advancing our scientific understanding of brain and nervous system function. Applications of these technologies span advancing understanding of neural function to translational methods that improve clinical outcomes.
The Regenerative Engineering and Medicine (REM) research center is a joint collaboration between Emory University and Georgia Tech.
REM is specifically focused on endogenous repair or how the body can harness its own potential to heal or regenerate. Bone, muscle, nerves, heart, blood vessels, and other tissues each have a baseline ability to regenerate. REM investigators ask what can be done when trauma or disease in humans overwhelms the ability of tissues or organs to regenerate on their own.